GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Enlivex Therapeutics
Enlivex is an Israeli biotech company developing cell therapies. Its stock price is driven by news of clinical trials. The price chart is a bet on the success of its scientific platform.
Share prices of companies in the market segment - Pharma immune
Enlivex Therapeutics is an Israeli biopharmaceutical company developing cell therapies to restore immune system balance in sepsis and other severe conditions. We've categorized it under "Pharma: Immunology." The chart below shows the dynamics in this cutting-edge sector.
Broad Market Index - GURU.Markets
Enlivex is an Israeli biopharmaceutical company developing cell therapies to treat conditions associated with immune system dysfunction, such as sepsis. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
ENLV - Daily change in the company's share price Enlivex Therapeutics
Enlivex Therapeutics Ltd.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its immunotherapy drugs.
Daily change in the price of a set of shares in a market segment - Pharma immune
Enlivex Therapeutics Ltd. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ENLV, which focuses on immunotherapy, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Enlivex Therapeutics is an Israeli biotech company developing therapies for conditions related to immune system dysfunction. Its shares are driven by news of clinical trials, adding an element of high scientific volatility to the overall market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Enlivex Therapeutics
Enlivex Therapeutics' year-end performance is a story about the development of its immunotherapy platform, Allocetra. Its 12-month market cap depends entirely on clinical trial data. Success in treating conditions such as sepsis or cytokine storm could be a real breakthrough in critical care medicine.
Annual dynamics of market capitalization of the market segment - Pharma immune
Enlivex Therapeutics Ltd. is an Israeli clinical-stage biotechnology company developing immunotherapy. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Enlivex Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Enlivex Therapeutics
Enlivex is an Israeli clinical-stage biotech company. Its monthly performance is entirely dependent on the results of its immunology clinical trials. Data from its lead drug, Allocetra, is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Enlivex Therapeutics develops immunotherapies to treat conditions associated with immune system dysfunction, such as sepsis. This is one of the most challenging areas in medicine. The dynamics of the biotech sector reflect investors' hopes for scientific breakthroughs. The Enlivex story is a risky bet that its platform can "reprogram" the immune response.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Enlivex Therapeutics Ltd. is an Israeli clinical-stage biopharmaceutical company developing cell therapies for conditions associated with immune system dysfunction. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its scientific breakthroughs have impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Enlivex Therapeutics
Enlivex, which develops innovative cell therapy for acute immune disorders, is extremely volatile. Weekly stock performance is a barometer of news about clinical trials of its Allocetra platform, particularly in complex areas such as sepsis and oncology, where there is a high need for new treatments.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Enlivex Therapeutics operates in the revolutionary cell therapy sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment, while failure can dampen investor interest. The chart will reveal whether the market perceives ENLV as a leader in this movement or simply part of it.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Enlivex Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how ENLV shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
ENLV - Market capitalization of the company Enlivex Therapeutics
Enlivex Therapeutics' market capitalization dynamics are another story of hope in immunotherapy. This Israeli biotech's chart reflects investor confidence in its platform for treating conditions associated with immune system overactivity. Its volatility reflects the market's assessment of the company's scientific potential and the risks involved in its path to approval.
ENLV - Share of the company's market capitalization Enlivex Therapeutics within the market segment - Pharma immune
Enlivex Therapeutics develops innovative cell therapies for conditions associated with immune system dysfunction, such as sepsis. Its market share in the biopharmaceutical sector reflects the potential of its Allocetra platform. The chart shows how the market perceives its chances of achieving a breakthrough in critical care.
Market capitalization of the market segment - Pharma immune
Enlivex Therapeutics develops cell therapies to treat conditions associated with immune system dysfunction. The chart below shows the market capitalization of the entire immunology pharmaceutical sector. Its dynamics reflect the hopes for the development of drugs capable of "rebooting" the immune system.
Market capitalization of all companies included in a broad market index - GURU.Markets
Enlivex Therapeutics develops cell therapies to treat conditions associated with immune system dysfunction, such as sepsis. Its market cap reflects its innovative approach. The chart below shows the economic weight of the advanced cell therapy sector.
Book value capitalization of the company, segment and market as a whole
ENLV - Book value capitalization of the company Enlivex Therapeutics
Enlivex Therapeutics is based on a unique cell therapy. The company's book value reflects its patents on the Allocetra platform for treating sepsis and other immune disorders, as well as cash flow for costly clinical trials. The chart below shows how the company is building a financial foundation for its breakthrough technology.
ENLV - Share of the company's book capitalization Enlivex Therapeutics within the market segment - Pharma immune
Enlivex Therapeutics, which develops cell therapies, has key tangible assets in the form of advanced R&D laboratories and manufacturing facilities. The S_BCap_Seg chart shows its share of innovative scientific infrastructure.
Market segment balance sheet capitalization - Pharma immune
Enlivex Therapeutics develops cell therapies for immune disorders. Its primary asset is its cutting-edge scientific platform, not its manufacturing facilities. A book value chart will show that its value is based on intangible assets and the potential for future drugs, which is typical of advanced biotechnology.
Book value of all companies included in the broad market index - GURU.Markets
Enlivex's book value is a scientific platform for rebooting the immune system. The company's assets consist of R&D laboratories, cell therapy equipment, and capital for clinical trials of Allocetra™. This material base is aimed at creating a breakthrough treatment for sepsis and solid tumors.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Enlivex Therapeutics
Enlivex Therapeutics develops macrophage-based therapies for the treatment of severe diseases. Its book value is derived from its cash reserves. Its market capitalization, however, is a bet on the success of its innovative cell therapy in clinical trials. This is a measure of the potential of its scientific platform, not its tangible assets.
Market to book capitalization ratio in a market segment - Pharma immune
Enlivex Therapeutics develops therapies to treat severe immune-related conditions. Its value lies in its scientific platform. The chart shows how the market values the life-saving potential of its technology, reflected in a premium to its book value, which consists of cash and equipment.
Market to book capitalization ratio for the market as a whole
Enlivex Therapeutics develops cell therapies for immune disorders. The company's value lies in its scientific platform, not its tangible assets. The market evaluates the potential for developing a new treatment approach. The chart illustrates how investor expectations are driving market capitalization away from its modest book value.
Debts of the company, segment and market as a whole
ENLV - Company debts Enlivex Therapeutics
Enlivex Therapeutics, a biotech company developing immunotherapy, uses debt to finance its research. This chart shows how the company raises capital to conduct clinical trials of its innovative cell therapies. This financial strategy is aimed at achieving breakthroughs in the treatment of serious diseases.
Market segment debts - Pharma immune
Enlivex Therapeutics is a clinical-stage biotech developing macrophage-based therapies. Like other companies in this field, it has no commercial products and relies entirely on raised equity capital to fund its research. This chart shows its financial position and R&D expenditure rate.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Enlivex Therapeutics
Enlivex Therapeutics is developing cell therapies for immune diseases. This chart shows whether the company uses debt financing. For a biotech company in the development stage, where success is uncertain, raising debt is a bold move. It demonstrates management's faith in its projects, but it also greatly increases the risks for shareholders.
Market segment debt to market segment book capitalization - Pharma immune
Enlivex Therapeutics is a biotech company working in the field of immunotherapy. This chart for the biotech sector shows how much capital is raised to fund breakthrough but risky research. It helps understand how the company's financial position is typical for this knowledge- and capital-intensive industry.
Debt to book value of all companies in the market
Enlivex Therapeutics develops innovative treatments to restore balance to the immune system. This chart, which shows the market's debt-to-book value ratio, is important for assessing the investment climate in biotech. The market's willingness to finance debt in this sector directly impacts Enlivex's ability to advance its expensive research.
P/E of the company, segment and market as a whole
P/E - Enlivex Therapeutics
Enlivex Therapeutics develops cell therapies to treat severe conditions associated with immune system dysfunction, such as sepsis. This chart reflects the company's belief in its innovative approach. Its value reflects the risk investors are willing to take in anticipation of a breakthrough in the treatment of life-threatening conditions, potentially turning the company's drug into a blockbuster.
P/E of the market segment - Pharma immune
Enlivex Therapeutics is a biotech company. This chart shows the average P/E ratio for the biotech sector, reflecting investors' overall faith in scientific breakthroughs. Comparing a company's P/E to this benchmark helps understand whether investors consider its cell therapy more or less promising than the average development in this innovative industry.
P/E of the market as a whole
Enlivex Therapeutics develops cell therapies to treat severe conditions associated with immune system dysfunction. The company's valuation is based on the potential of its Allocetra platform. This chart shows the overall risk appetite in biotech. It helps understand whether the market believes in the breakthrough potential of Enlivex's technology and how clinical news impacts its valuation relative to overall trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Enlivex Therapeutics
Enlivex Therapeutics is developing cell therapies to treat conditions associated with immune system dysfunction, such as sepsis. The chart illustrates investor expectations, which are entirely dependent on clinical trial results. This is a bet that the company's technology will offer a breakthrough treatment for critically ill patients.
%20P%2FE%20Enlivex%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Enlivex-Therapeutics&v=1772668798630 "Chart of the company's future (projected) P/E Enlivex Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Enlivex Therapeutics is developing innovative cell therapy to reprogram the immune system for the treatment of sepsis and solid tumors. This chart shows its future profitability expectations, allowing us to assess how highly the market values its breakthrough approach to treating critical conditions.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772668798679 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Enlivex Therapeutics develops innovative cell therapies for the treatment of conditions associated with immune system dysfunction. Like many biotech companies, its valuation is determined by investors' faith in the scientific platform and progress in clinical trials, rather than by the macroeconomic forecasts discussed here.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772668798741 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Enlivex Therapeutics
Enlivex Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of immune dysfunction conditions, such as sepsis. Its financial metrics reflect clinical trial expenses. This chart shows the investment in developing potentially breakthrough treatments for critical conditions.
Profit of companies in the market segment - Pharma immune
Enlivex Therapeutics is a clinical-stage biopharmaceutical company developing macrophage-based therapies for the treatment of complex conditions such as sepsis and solid tumors. This chart shows the profitability of the immunology segment. The company's current R&D costs reduce the overall profitability of the sector, but its innovative platform has the potential to be a breakthrough in the treatment of critical conditions.
Overall market profit
Enlivex Therapeutics develops immunotherapeutic drugs to treat conditions associated with immune dysfunction. The company's success depends on clinical trial results and recognition from the medical community. This overall profitability chart illustrates the state of the economy, which has little impact on the underlying logic of innovative biotechnologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Enlivex Therapeutics
Enlivex Therapeutics develops immunotherapy for conditions associated with immune system dysfunction. This chart reflects analysts' expectations for future earnings, based on the potential of its drug candidates for treating sepsis and other serious diseases. It demonstrates the market's confidence in the company's ability to successfully complete clinical trials.
%20profit%20of%20the%20company%20Enlivex%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Enlivex-Therapeutics&v=1772668798972 "Graph of future (projected) profit of the company Enlivex Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Enlivex Therapeutics is developing immunotherapy to reprogram macrophages to treat serious diseases. This chart shows profitability forecasts for the immunology pharmaceutical segment. It reflects general expectations for breakthrough cell therapies, which are the focus of Enlivex's clinical development.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772668799030 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Enlivex Therapeutics develops cell therapy. Like many biotech companies, Enlivex's overall market revenue forecast is important for its investment climate. Economic growth expectations, reflected in the chart, increase investor risk appetite and facilitate fundraising for costly clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772668799062 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Enlivex Therapeutics
Enlivex Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapy. The company has no sales revenue yet. Sales revenue will become critical after the approval of its drugs. The chart will show how the market evaluates initial revenue, factoring in the potential of its entire scientific platform for treating serious diseases.
P/S market segment - Pharma immune
Enlivex Therapeutics is developing innovative immunotherapy for conditions associated with immune system dysfunction, such as sepsis. Their technology has the potential to save lives. This chart shows the market premium the company is willing to pay for their breakthrough scientific approach and future revenue compared to other companies in the immunotherapy sector.
P/S of the market as a whole
Enlivex Therapeutics develops immunotherapy for conditions involving immune dysfunction, such as sepsis. Revenue is not yet available, and its market cap reflects hopes for a breakthrough in the treatment of critical conditions. This chart, showing the estimated real revenue, emphasizes that Enlivex's valuation reflects an investment in science and long-term prospects.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Enlivex Therapeutics
Enlivex Therapeutics is developing innovative cell therapy for conditions associated with immune system dysfunction, such as sepsis. This graph reflects investor expectations for future revenue from this breakthrough technology. It is essentially a bet on the company's ability to successfully commercialize its unique treatment approach.
%20P%2FS%20Enlivex%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Enlivex-Therapeutics&v=1772668799462 "The graph of the company's future (projected) P/S Enlivex Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company developing immunotherapies to reprogram the immune system to treat severe diseases. This chart shows how the market perceives the future commercial potential of its innovative Allocetra platform. It compares it to other immunology companies, reflecting confidence in its breakthrough technology.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772668799529 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Enlivex Therapeutics is developing immunotherapy for conditions associated with immune system dysfunction. The company's technology has potential applications in various fields of medicine. This chart shows overall investor revenue forecasts, and Enlivex demonstrates how platform biotechnologies are generating investor expectations for multiple sources of future revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772668799571 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Enlivex Therapeutics
Enlivex Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for conditions associated with immune system dysfunction. This chart does not include revenue from product sales, as the company's drugs have not yet been commercialized. Revenue may come from grants or partnerships.
Sales of companies in the market segment - Pharma immune
Enlivex Therapeutics is a biotech company developing immunotherapy. At this stage, its revenue is likely generated through partnerships and grants. This chart allows investors to see the sources of funding for its research, which is an important indicator of support for its scientific platform.
Overall market sales
Enlivex Therapeutics develops cell therapies for the treatment of serious diseases. Like many biotech companies, its prospects depend on scientific breakthroughs, not macroeconomics. This chart of the overall market trend does not reflect Enlivex's specific drivers, which lie in clinical trials and regulatory approvals.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Enlivex Therapeutics
Enlivex Therapeutics develops immunotherapy for the treatment of immune dysfunction conditions, such as sepsis. Its revenue forecast is dependent on the success of clinical trials. This chart reflects analysts' speculative expectations for the commercial potential of its innovative approach to modulating the immune response.
%20sales%20of%20the%20company%20Enlivex%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Enlivex-Therapeutics&v=1772668799692 "Schedule of future (projected) sales of the company Enlivex Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Enlivex Therapeutics develops cell therapies for the treatment of autoimmune diseases and sepsis. This chart shows projected revenues for the entire immunology segment. It provides insight into the size and growth analysts expect of the advanced cell therapy market, which is key to assessing the commercial potential of Enlivex's innovative platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772668799757 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Enlivex Therapeutics develops immunotherapy for conditions associated with immune system dysfunction. The company's success depends on the results of clinical trials. The overall economic situation, shown in this chart, influences the investment climate. Positive market expectations facilitate the attraction of capital needed to fund R&D.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772668799783 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Enlivex Therapeutics
Enlivex Therapeutics is a clinical-stage biopharmaceutical company developing macrophage-based therapies. This chart reflects its current focus on research. It doesn't show profit, but rather the effectiveness of managing capital invested in clinical trials, the success of which determines the company's entire future value.
Market segment marginality - Pharma immune
Enlivex Therapeutics develops innovative cell therapies for the treatment of severe immune and inflammatory conditions, such as sepsis. This chart illustrates the average profitability in the immunotherapy sector. It serves as a benchmark for assessing the potential profitability of Enlivex's Allocetra platform if it proves clinically and commercially viable.
Market marginality as a whole
Enlivex Therapeutics develops innovative cell-based therapies to combat sepsis and other serious diseases. This total revenue chart shows the state of existing markets, while Enlivex strives to achieve breakthroughs in medicine, where the potential return on successful treatments is enormous and unaffected by economic cycles.
Employees in the company, segment and market as a whole
Number of employees in the company Enlivex Therapeutics
Enlivex Therapeutics is a biopharmaceutical company developing cell therapies for immune disorders. Its team consists of scientists and clinical research specialists. Growth on this chart indicates progress in clinical programs and expansion of research, which is key for the company at this stage.
Share of the company's employees Enlivex Therapeutics within the market segment - Pharma immune
Enlivex Therapeutics is developing immunotherapy to treat conditions associated with immune system dysfunction. This chart illustrates its scientific potential. It reflects the percentage of leading immunologists and cell biologists working on an innovative platform for "rebooting" the immune system that this cutting-edge biotech company brings together under its wing.
Number of employees in the market segment - Pharma immune
Enlivex Therapeutics develops immunotherapies to reprogram immune cells to treat severe diseases. This chart shows employment in the immunology sector. The rapid growth of scientists in this field reflects the revolution in treatment and the massive investment in immune response management technologies, where Enlivex is seeking to carve out its niche.
Number of employees in the market as a whole
Enlivex Therapeutics develops cell therapies for immune diseases. The biotech sector, while not the largest employer, creates high-paying jobs. This chart illustrates how the innovative and knowledge-intensive industries in which Enlivex operates contribute qualitatively to the overall employment structure.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Enlivex Therapeutics (ENLV)
Enlivex Therapeutics is a clinical-stage immunotherapy company. Its market valuation is based solely on scientific potential. This chart shows the "value of hope" per employee. Investors evaluate not current performance, but the likelihood of a future breakthrough created by a small team of scientists.
%20of%20the%20company%20Enlivex%20Therapeutics%20(ENLV)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Enlivex-Therapeutics-ENLV&v=1772668800255 "Chart of market capitalization per employee (in thousands of dollars) of the company Enlivex Therapeutics (ENLV)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Enlivex Therapeutics is a biotech company developing immunotherapy. Its value is determined not by its headcount, but by its research potential. Its high market capitalization per employee, compared to the sector, indicates that the market is pricing in high expectations for its clinical programs, which are led by a relatively small team.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772668800262 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Enlivex Therapeutics is a clinical-stage biotech company developing therapies for conditions associated with immune system dysfunction. Its value is determined by the potential of its scientific developments. This chart reflects how investors value the intellectual capital of a small team of scientists working on innovative treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772668800284 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Enlivex Therapeutics (ENLV)
Enlivex Therapeutics is a biotech company developing immune cell-based treatments (for example, for sepsis). The company has no revenue; its business is science. This chart is in negative territory. It shows how much capital the company invests (spends) on each scientist trying to create breakthrough cell therapies.
%20Chart%20Enlivex%20Therapeutics%20(ENLV)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Enlivex-Therapeutics-ENLV&v=1772668800290 "Company Profit Per Employee (in thousands of dollars) Chart Enlivex Therapeutics (ENLV)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Enlivex Therapeutics develops cell therapies to treat severe immune and inflammatory diseases. This chart reflects the value of their scientific platform. For a biotech company, it illustrates the potential profitability of a breakthrough technology created by a small team of highly skilled scientists, a key metric for investors in this innovative field.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772668800424 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Enlivex Therapeutics is a clinical-stage biopharmaceutical company working on immunotherapy. This metric reflects current research and development costs per employee. There is no profit yet, so the graph shows the "cost" of a team of scientists advancing drugs (like Allocetra) through complex clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772668800462 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Enlivex Therapeutics (ENLV)
Enlivex Therapeutics is a clinical-stage biotechnology company. This chart shouldn't be interpreted as an indicator of current performance, as revenue is not reported. It represents scientific potential. Success in drug development and subsequent commercialization will lead to a sharp increase in this metric in the future.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Enlivex-Therapeutics-ENLV&v=1772668800549 "Sales chart per company employee Enlivex Therapeutics (ENLV)")
Sales per employee in the market segment - Pharma immune
Enlivex Therapeutics (ENLV) is an Israeli biopharmaceutical company developing macrophage-based therapies for sepsis, COVID-19, and solid tumors. This chart shows the average revenue per employee in the pharmaceutical segment. For Enlivex, which is in the R&D stage, comparing it to this benchmark (which is low) demonstrates their focus on the science and potential of future drugs, rather than current sales.
Sales per employee for the market as a whole
Enlivex Therapeutics is a clinical-stage biotech company working in the field of immunology. Like Akari, this metric doesn't yet reflect efficacy. There's no revenue, and investments are being made in R&D personnel. The timeline will only become meaningful if clinical trials are successful and their therapeutic platform is subsequently commercialized.
Short shares by company, segment and market as a whole
Shares shorted by company Enlivex Therapeutics (ENLV)
Enlivex Therapeutics is an Israeli biotech company developing a cell therapy (Allocetra) for the treatment of sepsis and cytokine storms. These are among the most challenging targets in medicine. This chart shows the number of bears betting that Enlivex will fail where dozens of others have failed, and that their therapy will prove ineffective.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Enlivex-Therapeutics-ENLV&v=1772668800806 "Short Shares Chart for the Company Enlivex Therapeutics (ENLV)")
Shares shorted by market segment - Pharma immune
Enlivex is an Israeli biotech developing a complex cell therapy (Allocell) to "reboot" the immune system in sepsis and cancer. This chart shows pessimism across the entire immunology sector. The rise in short positions across the industry is a "risk-off" signal. Investors are skeptical of complex and expensive cell technologies, expecting trial failures. This is weighing on the valuations of all risky biotechs, including ENLV.
Shares shorted by the overall market
Enlivex Therapeutics is developing therapies to modulate the immune system, targeting sepsis and cancer. These are complex and life-threatening conditions. This chart illustrates the general fear. When investors are pessimistic, they are skeptical of biotechs taking on the most challenging targets (sepsis is a trial "graveyard"). The risk of failure seems too high, and ENLV shares are selling off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Enlivex Therapeutics (ENLV)
Enlivex (ENLV) develops immunotherapeutic drugs targeting sepsis and solid tumors. This is a cutting-edge but risky area of biotech. This chart measures price momentum. It helps identify when the stock is entering overbought territory (above 70) on trial news or oversold territory (below 30) with no news flow.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Enlivex-Therapeutics-ENLV&v=1772668801132 "RSI 14 indicator chart for the company's stock Enlivex Therapeutics (ENLV)")
RSI 14 Market Segment - Pharma immune
Enlivex (ENLV) is an Israeli biotech company developing a therapy (Allocetra) that "reboots" the immune system to treat sepsis and solid tumors. This chart tracks overall sentiment in the Pharma/Immunology sector. It helps investors understand whether the entire sector is overheated by immunotherapy hype or oversold.
RSI 14 for the overall market
Enlivex (ENLV) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ENLV (Enlivex Therapeutics)
Enlivex (ENLV) is an Israeli biopharmaceutical company developing Allocetra, a cell therapy designed to "rebalance" the immune system in life-threatening conditions such as sepsis. This chart shows the speculative average price target from analysts based on their belief in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ENLV-Enlivex-Therapeutics&v=1772668801345 "A chart showing analyst consensus forecasts for the expected stock price. ENLV (Enlivex Therapeutics)")
The difference between the consensus estimate and the actual stock price ENLV (Enlivex Therapeutics)
Enlivex is an Israeli biotech company developing a cell therapy (Allocetra) to "reboot" the immune system in sepsis and cancer. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in this complex yet groundbreaking R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ENLV-Enlivex-Therapeutics&v=1772668801523 "A chart showing the difference between the consensus forecast and the actual stock price. ENLV (Enlivex Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Enlivex (ENLV) is an Israeli biotech company developing Allocetra, a cell therapy designed to "reboot" the immune system in sepsis and solid tumors. This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe in this R&D approach to treating the "inflammatory storm."
Analysts' consensus forecast for the overall market share price
Enlivex Therapeutics (ENLV) is an Israeli biopharmaceutical company. They are developing a drug (Allocetra) that is designed to "reboot" the immune system to treat sepsis and cancer. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk R&D platforms in immunology.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Enlivex Therapeutics
Enlivex Therapeutics is an Israeli clinical-stage biotech company focused on immunology. Their R&D platform (Allocetra) is a cell therapy designed to reboot and calm an overactive immune system (for example, in sepsis or cancer). This chart is a clear indicator of faith in their deep science, reflecting their (highly risky) R&D progress.
AKIMA Market Segment Index - Pharma immune
Enlivex Therapeutics (ENLV) is an Israeli immunotherapy company developing Allocetra, a drug designed to reboot the immune system in conditions associated with an overreaction, such as sepsis. The chart shows the average index for the segment, helping investors assess how this innovative therapy compares to the average risk in the sector.
The AKIM Index for the overall market
Enlivex Therapeutics is an Israeli cellular immunotherapy company (Allocetra). It reprograms macrophages to treat sepsis and solid tumors. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative platform compares to overall economic trends.
